



Partner with Pitt Cell and Gene Therapy



Accelerating Cell and Gene Therapy Breakthroughs

Recognizing that cell and gene therapies represent the future of medicine, the University of Pittsburgh has more than **60 active faculty** pursuing groundbreaking advancements in the field, **world-renowned research facilities**, and our new **Pitt BioForge Biomanufacturing Facility**. From bench to bedside, partnering with Pitt can help to advance your cell and gene therapies.

Collaborate with more than 60 faculty conducting cell and gene therapy (C>) research



Primary Therapeutic Areas

- Cardiovascular/Metabolic Disease
- Hematology
- Hepatology
- Immunology
- Infectious Disease
- Musculoskeletal
- Nephrology
- Neuroscience
- Oncology
- Ophthalmology
- Otolaryngology
- Reproductive Health

See highlighted faculty members on the reverse side of this page.



University of Pittsburgh to Build \$100M Biomanufacturing and Research Hub

Pitt and ElevateBio have partnered to bring cell and gene therapy manufacturing to the Pittsburgh region. The project, known as Pitt BioForge, will bring every stage of life science innovation under one roof to develop new cell and gene therapies and other treatments and products.

“We have some exceptional emerging research coming out of the University of Pittsburgh,” says Pitt’s Senior Vice Chancellor for the Health Sciences Anantha Shekhar, MD, PhD. “The missing ingredient has been access to high-quality process science and manufacturing capabilities. As we position ourselves to become the next global hub for life sciences and biotech, we were in search for the right partner to help us realize our vision.”



Scan the QR Code to read the latest on Pitt’s BioForge Biomanufacturing Center



For more information on partnering with Pitt for cell and gene therapy research and/or licensing available technologies, contact:

Jon Fura, PhD
Director, Industry Partnerships
Office of Industry and Economic Partnerships
Jon.fura@pitt.edu

Partner with Pitt

Cell and Gene Therapy Highlighted Faculty

Pitt investigators are advancing groundbreaking research on several cell and gene therapies.



Neuroscience



Robert M. Friedlander, MD

Research Interests:

Treatment strategies for diseases such as Huntington's disease, ALS, stroke, brain trauma, and spinal cord injury through modulation of the caspase-family apoptotic pathways; restoration of mitochondrial function to inhibit neurodegeneration as a treatment for Huntington's disease



Rebecca Seal, PhD

Research Interests:

Novel gene therapies targeting the spinal dorsal horn to treat intractable pain, molecular mechanisms involved with the motor symptoms of Parkinson's disease to develop new treatments

Oncology



Greg DelGoffe, PhD

Research Interests:

Therapeutic improvement of CAR T cell function via metabolic reprogramming, reactivation of T cell mitochondrial function within tumor microenvironments for tumor-infiltrating lymphocyte (TIL) therapy



Udai Kammula, MD

Research Interests:

Developing adoptive cell therapies for the treatment of various cancers, including melanoma, using tumor-infiltrating lymphocytes (TIL) and engineered T cells with unique receptors

Cardiovascular and Metabolic Disease



Jason Becker, MD

Research Interests:

Molecular mechanisms regulating genetic and acquired cardiomyopathies to identify novel methods to prevent heart failure



Robert Nicholls, PhD

Research Interests:

Developing polycistronic AAV vectors that enable expansion of the genetic payload for the treatment of diseases that are associated with genetic mutations of multiple genes such as Prader-Willi Syndrome



Iain Scott, PhD

Research Interests:

Mitochondrial dysfunction in the development of diseases such as diabetes, ischemia, and heart failure



Gerald Vockley, MD, PhD

Research Interests:

Elucidating genetic causes in disorders associated with energy metabolism and amino acid catabolism such as VLCAD deficiency, cholesterol synthesis, and type 2 diabetes

Ophthalmology



Leah Byrne, PhD

Research Interests:

Engineering viral vectors with new abilities and improved capabilities to deliver therapeutic genes; developing new therapies that allow for increased precision of gene delivery and protein expression



Debasish Sinha, PhD

Research Interests:

Lysosome/autophagy degenerative processes in retinal pigmented-epithelial cells involved in age-related macular degeneration



For more information on partnering with Pitt for cell and gene therapy research and/or licensing available technologies, contact:

Jon Fura, PhD
Director, Industry Partnerships
Office of Industry and
Economic Partnerships
Jon.fura@pitt.edu